Gilenya Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis
Condition:   Multiple Sclerosis Intervention:   Drug: Gilenya®; Novartis Pharmaceuticals Corporation Sponsor:   Universitätsklinikum Hamburg-Eppendorf Recruiting - verified July 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2017 Category: Research Source Type: clinical trials